#Vitrakvi

FDA Approves Vitrakvi for All Cancers With Specific Gene Mutation

The FoundationOne CDx test identifies solid tumors with NTRK fusions.

New site-agnostic therapies highlight the importance of genetic testing.

AACR report highlights progress in preventing and treating cancer—including 27 new drug approvals last year—but disparities persist.

The Food and Drug Administration may approve the next site-agnostic treatment in August.

An ongoing study is assessing pediatric and young adult cancers that did not respond to initial treatments.

Researchers continue to develop new drugs that target cancer with specific genetic mutations anywhere in the body.

A look back at some of the major news stories we covered this year.

Here are the cancer treatment news stories with the most views this year.

The FDA recently approved Vitrakvi for all cancers with specific gene mutation.

New drug Vitrakvi targets specific receptor kinase that promotes tumors.

Larotrectinib and entrectinib are effective against cancer with specific genetic changes anywhere in the body.

New drug targets RET mutations in multiple cancer types.

TRK fusions occur in less than 1 percent of cancers—but when treated with larotrectinib, patients have seen dramatic results.